The Complete Guide to Relugolix: From Molecular Science to Global Sourcing for Manufacturers
Relugolix (marketed as Orgovyx) represents a significant advancement in androgen deprivation therapy (ADT) for advanced prostate cancer.
As the first and only oral gonadotropin-releasing hormone (GnRH) receptor antagonist approved by the FDA, it offers patients an effective alternative to traditional injectable therapies.
This comprehensive guide explores everything from its mechanism of action and clinical efficacy to cost considerations and side-effect management, providing patients and caregivers with essential information for making informed treatment decisions.
What is Relugolix?
Relugolix is a prescription medication classified as a gonadotropin-releasing hormone (GnRH) receptor antagonist.
It is specifically designed for the treatment of advanced prostate cancer in adult men.
Chemically known as TAK-385 or RVT-601, relugolix directly blocks GnRH receptors in the pituitary gland, leading to rapid reductions in luteinizing hormone (LH) and follicle-stimulating hormone (FSH) production.
This action suppresses testosterone production by the testes—a crucial therapeutic goal in managing hormone-sensitive prostate cancer.
Unlike traditional GnRH agonists (such as leuprolide), which initially stimulate testosterone production before suppressing it (causing a “flare” phenomenon), relugolix immediately inhibits hormone signaling.
This mechanism allows for rapid testosterone suppression without the initial surge that can exacerbate cancer symptoms in some patients.
Key Fact: Relugolix received FDA approval in December 2020 based on the results of the pivotal HERO clinical trial, marking it as the first oral hormone therapy for advanced prostate cancer.
What are the Relugolix Brand Names?
Relugolix is primarily marketed under the brand name Orgovyx.
This is the name under which it is prescribed and dispensed in the United States and several other countries.
During its development and in various global markets, relugolix has been known by several other names:
TAK-385: The development code used by Takeda Pharmaceutical Company during clinical trials
RVT-601: Another research designation for the compound
In scientific literature and pharmaceutical sourcing contexts, you may encounter relugolix by its chemical name: 1-{4-[1-(2,6-difluorobenzyl)-5-[(dimethylamino)methyl]-3-(6-methoxypyridazin-3-yl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl]phenyl}-3-methoxyurea.
It’s important to note that while “relugolix” is the generic (non-proprietary) name of the active pharmaceutical ingredient, Orgovyx is the specific branded product that contains this ingredient in tablet form for oral administration.
How Much Does Relugolix Cost? (Relugolix Price)
The cost of relugolix (Orgovyx) varies significantly depending on insurance coverage, pharmacy, and geographic location.
As a relatively new branded medication, it generally carries a higher price tag than older, generic ADT options.
Approximate Pricing Information:
According to available data, the price for relugolix 120 mg tablets through specific procurement programs, such as the VA Federal Supply Schedule (FSS), is approximately $57.71 per tablet.
Given the recommended dosing (one 120 mg tablet daily after an initial loading dose), the monthly medication cost would be approximately $1,731.
For research or pharmaceutical manufacturing purposes, the active pharmaceutical ingredient (Relugolix API) is available in smaller quantities at varying prices, such as approximately $210/g for 10g from specific suppliers.
Important Cost Considerations:
Insurance Coverage: Most private insurance plans and Medicare Part D cover Orgovyx, but copays vary
Patient Assistance Programs: The manufacturer, Sumitomo Pharma America, offers support programs for eligible patients
Financial Assistance: Foundations and nonprofit organizations may provide aid for qualifying patients
Generic Availability: As a recently approved medication, generic versions are not yet available, which affects cost
Practical Tip: Patients should contact the Orgovyx Complete patient support program (1-833-696-8268) for personalized assistance with insurance verification, prior authorization, and copay assistance.
What is Relugolix Used For?
Relugolix has one primary, FDA-approved indication: the treatment of adult patients with advanced prostate cancer.
Advanced prostate cancer in this context typically includes:
Metastatic disease (cancer that has spread beyond the prostate to other parts of the body)
Locally advanced disease that is not amenable to curative treatment with surgery or radiation alone
Cases where androgen deprivation therapy (ADT) is medically appropriate
Beyond its approved use, clinical research is exploring other potential applications for relugolix, including:
Neoadjuvant therapy (before primary treatment) in combination with radiation for intermediate-risk prostate cancer
Female health conditions such as uterine fibroids and endometriosis (under different brand names and formulations)
Contraception (currently in clinical trials)
In prostate cancer management, relugolix may be used in various clinical scenarios:
As initial ADT for newly diagnosed advanced disease
In combination with other therapies such as novel antiandrogens (e.g., enzalutamide, abiraterone)
Adjuvant to radiation therapy for high-risk localized or locally advanced disease
For patients who prefer oral administration over injections or implants
For those who have experienced intolerable side effects from other forms of ADT
How Relugolix Works? (Mechanism of Action)
Relugolix operates through a precise endocrine mechanism that distinguishes it from traditional hormone therapies for prostate cancer.
Understanding this mechanism helps clarify both its benefits and potential side effects.
Step-by-Step Mechanism:
GnRH Receptor Antagonism: Relugolix is a competitive antagonist at the gonadotropin-releasing hormone (GnRH) receptors in the anterior pituitary gland. It binds to these receptors without activating them, preventing the natural GnRH from binding.
Suppression of Gonadotropins: By blocking GnRH signaling, relugolix rapidly reduces the production and release of two key hormones: luteinizing hormone (LH) and follicle-stimulating hormone (FSH).
Testosterone Reduction: LH normally stimulates the Leydig cells in the testes to produce testosterone. With LH suppressed, testicular testosterone production plummets rapidly, typically reaching castration levels (<50 ng/dL) within days.
Androgen Deprivation: Testosterone and its more potent metabolite, dihydrotestosterone (DHT), are the primary androgens (male hormones) that fuel prostate cancer growth. By reducing these to very low levels, relugolix starves the cancer cells of their growth signals.
Key Pharmacological Features:
High Potency: Relugolix has an IC50 (half-maximal inhibitory concentration) of 0.33 nM for human GnRH receptors, indicating strong binding affinity
Oral Bioavailability: Unlike other GnRH antagonists (e.g., degarelix), relugolix is effective when taken orally due to specific chemical modifications that enhance absorption
Rapid Onset: Therapeutic effects begin within days rather than weeks because there is no initial stimulation phase
Reversible Effect: Testosterone levels recover relatively quickly (typically within 3 months) after discontinuation, unlike some depot injections, which have prolonged effects.
Understanding Androgen Deprivation Therapy (ADT) Options
Before comparing relugolix specifically to leuprolide, it’s helpful to understand the broader landscape of androgen deprivation therapy. The table below summarizes key characteristics of available ADT options.
Table: Comparison of Androgen Deprivation Therapy Options
| Characteristic | GnRH Antagonists (Relugolix, Degarelix) | GnRH Agonists (Leuprolide, Goserelin) | Antiandrogens (Bicalutamide, Darolutamide) |
|---|---|---|---|
| Primary Mechanism | Directly block GnRH receptors | Initially stimulate then downregulate GnRH receptors | Block androgen receptors on cancer cells |
| Administration | Oral (relugolix) or injection (degarelix) | Intramuscular or subcutaneous injections | Oral tablets |
| Testosterone Flare | No flare effect | Initial testosterone surge (flare) possible | No impact on testosterone production |
| Onset of Action | Rapid (days) | Slower (weeks) with initial flare | Rapid (days) |
| Common Side Effects | Hot flashes, fatigue, weight gain | Hot flashes, fatigue, and bone density loss | Fatigue, hot flashes, falls/fractures |
This context helps explain why relugolix represents an essential addition to the ADT arsenal, particularly for patients who need rapid testosterone suppression without flare or who prefer oral administration.
Relugolix vs Leuprolide: A Detailed Comparison
The comparison between relugolix and leuprolide (a GnRH agonist commonly marketed as Lupron) is critical, as leuprolide has been a standard ADT option for decades.
The pivotal HERO trial directly compared these two treatments.
Efficacy Comparison:
Table: Efficacy Outcomes from the HERO Trial (Relugolix vs Leuprolide)
| Outcome Measure | Relugolix | Leuprolide | Clinical Significance |
|---|---|---|---|
| Sustained castration rate (<50 ng/dL from day 29 to 337) | 96.7% | 88.8% | Relugolix demonstrated superiority (7.9% more patients maintained castration) |
| Profound castration rate (<20 ng/dL at day 15) | 78.4% | 0.98% | Relugolix achieved much faster and deeper suppression |
| Time to castration (<50 ng/dL) | 56% by day 4, 99% by day 15 | 0% by day 4, 12% by day 15 | Relugolix works significantly faster |
| Major adverse cardiac events (MACE) | 2.9% | 6.2% | Relugolix showed a 54% lower risk of MACE |
Key Differences Explained:
Mechanism of Action:
Relugolix is a GnRH antagonist that immediately blocks hormone signaling
Leuprolide is a GnRH agonist that initially stimulates and then suppresses hormone signaling
Testosterone Flare Phenomenon:
Relugolix: No flare effect—testosterone decreases immediately
Leuprolide: Initial flare occurs in most patients—testosterone increases before decreasing, which can temporarily worsen symptoms
Administration and Convenience:
Relugolix: Oral daily tablet—can be self-administered at home
Leuprolide: Injection every 1-6 months (depending on formulation)—requires clinic visits for administration
Cardiovascular Safety:
The HERO trial showed significantly fewer major adverse cardiac events with relugolix compared to leuprolide (2.9% vs 6.2%)
This may be particularly important for patients with pre-existing cardiovascular conditions
Recovery After Discontinuation:
Relugolix: Testosterone recovery is faster after stopping treatment
Leuprolide: Testosterone recovery is slower due to the depot formulation’s prolonged release
When Relugolix May Be Preferable:
Patients needing rapid testosterone suppression (e.g., those with impending spinal cord compression or severe bone pain)
Those with significant cardiovascular risk factors
Patients who prefer oral administration or have difficulty with clinic visits for injections
Individuals who have experienced problematic flare reactions with GnRH agonists
Relugolix Precautions and Drug Interactions
Important Precautions:
QT Interval Prolongation:
Androgen deprivation therapy, including relugolix, may prolong the QT interval on electrocardiograms
Use with caution in patients with:
Congenital long QT syndrome
Congestive heart failure
Frequent electrolyte abnormalities
Those taking other QT-prolonging medications
Monitoring recommendation: Consider periodic ECGs and electrolyte monitoring
Hypersensitivity Reactions:
Relugolix can cause hypersensitivity reactions, including severe cases of angioedema (swelling beneath the skin)
The medication is contraindicated in patients with known severe hypersensitivity to relugolix or any product components
Action: Withhold relugolix if hypersensitivity symptoms occur; discontinue permanently for severe reactions
Embryo-Fetal Toxicity:
Relugolix can cause fetal harm based on its mechanism of action and animal studies
Male patients with female partners of reproductive potential should use effective contraception during treatment and for 2 weeks after the last dose
Bone Density Effects:
Like all ADT, relugolix can cause decreased bone density, potentially leading to osteoporosis and increased fracture risk
The product monograph includes a “black box” warning about this risk
Significant Drug Interactions:
Table: Important Drug Interactions with Relugolix
| Interacting Drug Class | Example Medications | Effect | Management Recommendation |
|---|---|---|---|
| P-glycoprotein (P-gp) inhibitors | Amiodarone, carvedilol, cyclosporine, quinidine | Increased relugolix exposure | Avoid concurrent use if possible. If unavoidable, separate administration by at least 6 hours (relugolix first). |
| Combined P-gp and strong CYP3A inducers | Rifampin, carbamazepine, phenytoin, St. John’s wort | Decreased relugolix exposure | Avoid concurrent use if possible. If unavoidable, increase the elugolix dose to 240 mg daily. |
| Other androgen deprivation therapies | Leuprolide, goserelin, degarelix, antiandrogens | Additive testosterone suppression | Generally not used together except in specific combination protocols under specialist supervision. |
Other Important Precautions:
Hepatic Impairment: No specific dose adjustment recommended for mild to moderate impairment; use with caution in severe impairment
Renal Impairment: No dose adjustment needed for any degree of renal impairment
Elderly Patients: No dose adjustment specifically required based on age alone
What Are the Side Effects of Relugolix?
Like all medications, relugolix can cause side effects. Understanding these potential effects helps patients and caregivers manage expectations and recognize when to seek medical attention.
Most Common Side Effects (from HERO trial):
The following side effects occurred in ≥10% of patients taking relugolix:
Table: Common Adverse Reactions with Relugolix
| Side Effects | Frequency (Relugolix) | Frequency (Leuprolide) | Typical Management |
|---|---|---|---|
| Hot flush | 54% | 52% | Lifestyle measures, take medications if severe |
| Increased glucose | 44% | 54% | Monitoring, diet, exercise, and medications |
| Increased triglycerides | 35% | 36% | Diet modification,lipid-lowering drugs |
| Musculoskeletal pain | 30% | 29% | Pain relievers, physical therapy |
| Decreased hemoglobin | 28% | 29% | Monitor, address if symptomatic |
| Increased ALT (liver enzyme) | 27% | 28% | Monitor, normally it resolves |
| Fatigue | 26% | 24% | Energy conservation, exercise |
| Increased AST (liver enzyme) | 18% | 19% | Monitor, normally it resolves |
| Constipation | 12% | 10% | Fiber, fluids, or use laxatives |
| Diarrhea | 12% | 7% | Hydration, dietary modification |
Less Common But Serious Side Effects:
Major adverse cardiac events: Myocardial infarction, stroke (2.9% in HERO trial)
Severe hypersensitivity reactions: Angioedema, anaphylaxis (rare but serious)
Hepatic toxicity: Significant liver enzyme elevations (monitoring recommended)
Bone fractures: Related to decreased bone mineral density with long-term use
Management Strategies for Common Side Effects:
Hot Flashes:
Dress in layers for easy adjustment
Avoid common triggers (spicy foods, caffeine, alcohol, stress)
Practice paced respiration techniques
Discuss medications (SSRIs, gabapentin, clonidine) if severe
Fatigue:
Prioritize and pace activities
Incorporate light to moderate regular exercise
Optimize sleep hygiene
Consider energy conservation techniques
Metabolic Changes (increased glucose, triglycerides):
Regular monitoring of blood glucose and lipids
Heart-healthy diet low in simple sugars and saturated fats
Regular physical activity
Medications as needed under medical supervision
Bone Health:
Ensure adequate calcium and vitamin D intake
Weight-bearing exercise when possible
Fall prevention strategies
Consider bone density monitoring and treatment if indicated
When to Contact Your Healthcare Provider Immediately:
Signs of allergic reaction: swelling of face/lips/tongue/throat, trouble breathing, hives
Symptoms of heart problems: chest pain, shortness of breath, palpitations, dizziness
Severe or persistent side effects that interfere with daily activities
Thoughts of self-harm or severe depression
How Long Does Relugolix Take to Work?
One of the distinguishing features of relugolix is its rapid onset of action.
Unlike GnRH agonists that may take weeks to achieve castration levels, relugolix begins working within days.
Timeline of Testosterone Suppression with Relugolix:
Day 4: 56% of patients achieve castration (<50 ng/dL)
Day 8: 91% achieve castration
Day 15: 99% achieve castration; 78% achieve profound castration (<20 ng/dL)
Day 29: 99% maintain castration; 95% achieve profound castration
Comparison with Leuprolide:
Day 4: 0% achieve castration (due to initial flare)
Day 15: 12% achieve castration; 1% achieve profound castration
Day 29: 82% achieve castration; 57% achieve profound castration
Clinical Implications of Rapid Action:
Symptom Relief: Patients with bone pain or other symptoms exacerbated by testosterone may experience faster symptom improvement
Avoidance of Clinical Flare: The absence of an initial testosterone surge prevents potential worsening of symptoms that can occur with GnRH agonists
Urgent Situations: May be preferred when rapid testosterone suppression is clinically significant (e.g., impending spinal cord compression)
Duration of Effect:
With daily dosing, testosterone suppression is maintained as long as treatment continues
If a dose is missed, testosterone levels may begin to rise within days, emphasizing the importance of consistent daily administration
Recovery After Discontinuation:
Testosterone levels typically recover more quickly after stopping relugolix compared to depot injections like leuprolide
In clinical studies, mean testosterone levels 3 months after discontinuation were approximately 288 ng/dL for relugolix versus 59 ng/dL for leuprolide
This more rapid recovery may be advantageous when ADT is paused or when fertility considerations are relevant
Global Sourcing Tips for Relugolix API
For pharmaceutical manufacturers, researchers, or compounding pharmacies interested in sourcing the relugolix active pharmaceutical ingredient (API), several considerations are essential.
Key Supplier Information:
Relugolix API is available from various global suppliers with different specifications and pricing:
Purity Levels: Typically 99% or higher for pharmaceutical use
Packaging: Available in quantities ranging from 1mg to kilogram scales
Pricing: Varies significantly by supplier and quantity (e.g., approximately $195.50 for 5mg from some suppliers)
Essential Considerations for Sourcing:
Quality and Regulatory Compliance:
Ensure suppliers operate under current Good Manufacturing Practices (cGMP)
Verify compliance with relevant regulatory authorities (FDA, EMA, etc.)
Request certificates of analysis and stability data
Consider suppliers with proven regulatory track records, such as those that have passed FDA inspections
Supplier Evaluation Criteria:
Regulatory history and inspection records
Manufacturing capabilities and capacity
Quality systems and documentation practices
Supply chain reliability and consistency
Technical support and responsiveness
Legal and Compliance Considerations:
Patent status: Relugolix is under patent protection in many jurisdictions
Regulatory approvals: Ensure intended use complies with local regulations
Import/export regulations: Particularly for controlled substances or prescription drug components
Practical Sourcing Tips:
Start with small test quantities before committing to larger purchases
Diversify suppliers when possible to mitigate supply chain risks
Establish clear quality agreements with specifications and testing protocols
Consider geopolitical factors that might affect supply chain continuity
Managing Sexual Side Effects and Considering Erectile Dysfunction Medications
A significant concern for many men starting ADT, including relugolix, is the impact on sexual function.
Testosterone suppression typically leads to decreased libido and erectile dysfunction.
Understanding the Impact:
Libido: Most men experience a significant decrease in sexual desire while on ADT
Erectile Function: The ability to achieve and maintain erections is typically diminished or absent during treatment
Emotional Impact: These changes can cause distress, frustration, and relationship strain
Management Approaches:
Open Communication:
Discuss concerns openly with your healthcare team and partner
Consider sexual health counseling or couples therapy
Remember that these effects are treatment-related, not personal
Medical Interventions:
Phosphodiesterase type 5 (PDE5) inhibitors like sildenafil (Viagra), tadalafil (Cialis), or vardenafil (Levitra) may help some men, though effectiveness is often reduced on ADT
Penile injection therapy or urethral suppositories (alprostadil)
Vacuum erection devices
Penile implants (surgical option for long-term solutions)
Non-Pharmacological Approaches:
Focus on intimacy beyond intercourse
Explore different forms of sexual expression
Consider sensate focus exercises with a partner
Essential Considerations with Erectile Dysfunction Medications:
PDE5 inhibitors like sildenafil are generally safe but require medical supervision, especially with cardiovascular conditions
Never combine ED medications without medical advice
Timing is essential—sildenafil typically works best when taken 30-60 minutes before sexual activity
Side effects may include headache, flushing, indigestion, or visual changes
When to Seek Specialist Care:
Consider consultation with a urologist specializing in sexual medicine if:
Standard approaches are insufficient
You have pre-existing conditions that complicate ED management
You’re interested in more advanced treatment options
Relugolix in Combination Therapies and Future Directions
Current Combination Approaches:
Relugolix is increasingly used in combination with other therapies for enhanced efficacy:
With Novel Antiandrogens: Combinations with drugs like enzalutamide or apalutamide for more complete androgen pathway blockade
With Chemotherapy: In metastatic hormone-sensitive prostate cancer (mHSPC)
With Radiation Therapy: As neoadjuvant/adjuvant treatment for localized disease
Ongoing Research and Future Applications:
Female Health Conditions: Relugolix is being studied (often in combination with estradiol and norethindrone acetate) for:
Uterine fibroids (approved in some countries as Myfembree)
Endometriosis-associated pain
Contraception: Clinical trials are investigating relugolix for male contraception
Pediatric Applications: Potential use in central precocious puberty (under investigation)
Other Cancers: Exploration in other hormone-sensitive cancers
Conclusion
Relugolix (Orgovyx) represents a paradigm shift in androgen deprivation therapy for advanced prostate cancer.
As the first oral GnRH antagonist, it offers unique advantages, including rapid onset of action without testosterone flare, potentially improved cardiovascular safety profile, and the convenience of oral administration.
For patients considering relugolix, the decision should involve careful discussion with their oncology team about:
Individual disease characteristics and treatment goals
Comorbid conditions, especially cardiovascular health
Lifestyle preferences regarding administration route
Cost considerations and insurance coverage
Potential side effects and management strategies
While relugolix may not be the optimal choice for every patient, it provides an essential additional option in the prostate cancer treatment arsenal.
Its development reflects ongoing efforts to create more targeted, convenient, and patient-centered cancer therapies.
Final Considerations:
Adherence is Critical: The effectiveness of daily oral therapy depends on consistent adherence.
Monitoring is Essential: Regular follow-up with your healthcare team ensures optimal management.
Holistic Approach: Prostate cancer treatment should address physical, emotional, and quality-of-life concerns
Stay Informed: Treatment options continue to evolve—maintain open communication with your medical team about new developments
For the most current information about relugolix, consult the official prescribing information, discuss with your healthcare provider, and visit reputable medical resources for updates on this important therapeutic option.
Disclaimer:
This content is for informational purposes only and is intended for business-to-business communication within the pharmaceutical industry. It is not intended as medical advice. The manufacture, import, and use of API must comply with all applicable laws and regulations in the relevant country or region.
This blog post is informational only and does not constitute medical advice.
Always consult a healthcare professional before starting any new medication or treatment.
Bonjour,
Y a t il une erreur dans ce texte publié? (voir ci dessous “Insuffisance hépatique et rénale)
Merci pour votre réponse
Cordialement
JLuc Gouilloux
“Autres précautions importantes :
Insuffisance hépatiqueAucun ajustement posologique spécifique n’est recommandé en cas d’insuffisance rénale légère à modérée ; utiliser avec prudence en cas d’insuffisance rénale sévère.
Insuffisance rénaleAucun ajustement posologique n’est nécessaire, quel que soit le degré d’insuffisance rénale.”
Oui, merci
Dopo 45 giorni di trattamento ai controlli risulta che il PSA è sceso da 11,6 a 0,2 e la recidiva prostatica da mm14x20 a 8x 9.
Prendo una compressa ogni notte alle ore 24 ma ieri notte mi è capitato di non prenderla. Senza alcuna modifica riprendo stanotte alle 24
Faccio bene? devo fare altro? Grazie
Dovresti consultare un medico locale